PharmaResources, established in 2007, is a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery, pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates.

Our new drug R&D services cover the entire process of preclinical new drug research, primarily including drug discovery and processR&D. In drug discovery, we assist clients in designing, screening, and optimizing hit compounds and lead compounds , conducting structural improvements, and preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights.In our process R&D servicewe provide new drug process chemistry services and innovative synthetic process development for global pharmaceutical companies,helping clients to achieve cost-effective, safe, green, and reliable commercial manufacturing of intermediates and APIs in scales from kilograms to tons. Leveraging our technological advantages in pharmaceutical process technology, we also engage in the customized manufacturing services of key drug intermediates,as well as independent research and development and manufacturing of specialty APIs intermediates with complex chemical structures and high synthesis difficulties.

In March 2021, PharmaResources' IPO application for GEM was accepted by the Shenzhen Stock Exchange. In April 2022, it successfully passed the review of the Listing Committee of the Shenzhen Stock Exchange.On July 8, 2022, the China Securities Regulatory Commission approved the application of PharmaResources (Shanghai) Co.,Ltd. for an initial public offering of stocks and listing on the Shenzhen GEM. On October 18, 2022, PharmaResources issued 19.25 million A-shares in its initial public offering and was listed on the GEM.

As advocated in the core values of PharmaResources, 'Science-driven, continuous innovation'.Regardless of how the internal and external environment may change, 'Science and Inn